Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more

116 Huntington Avenue, Boston, MA, 02116, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

898.4M

52 Wk Range

$7.80 - $19.71

Previous Close

$15.48

Open

$15.46

Volume

606,728

Day Range

$15.13 - $17.00

Enterprise Value

477.4M

Cash

290.2M

Avg Qtr Burn

-29.25M

Insider Ownership

12.16%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ficerafusp alfa + Pembrolizumab Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ficerafusp alfa -/+ Pembrolizumab Details 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ficerafusp alfa Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.